CAMBRIDGE, MA, USA I June 08, 2016 I Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company’s lead biosimilar candidate developed in collaboration with Baxalta, now part of Shire plc, will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London.
The poster, which summarizes topline results for a randomized, double-blind, three-arm, parallel group, single-dose study that was designed jointly by Momenta, Baxalta, and Quintiles, Inc., met its primary endpoint late last year. Pharmacokinetic, safety, and immunogenicity data for M923 compared with U.S.- and EU-sourced HUMIRA reference products will be presented.
Poster Presentation Details
Poster #FRI0182: A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (a Proposed Biosimilar to Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects
Presentation Date/Time: Friday, June 10, 2016; 11:45 a.m. local time
Presenter: Jan Hillson, MD; Vice President, Clinical Research, Momenta Pharmaceuticals
About M923, a proposed biosimilar of HUMIRA® (adalimumab)
M923 is developed in collaboration by Baxalta Incorporated, now part of Shire plc, and Momenta Pharmaceuticals. HUMIRA, the largest selling therapeutic on the market today, is a significant intervention for patients with autoimmune/inflammatory diseases. Adalimumab is used to treat many such conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
SOURCE: Momenta Pharmaceuticals
Post Views: 60
CAMBRIDGE, MA, USA I June 08, 2016 I Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company’s lead biosimilar candidate developed in collaboration with Baxalta, now part of Shire plc, will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London.
The poster, which summarizes topline results for a randomized, double-blind, three-arm, parallel group, single-dose study that was designed jointly by Momenta, Baxalta, and Quintiles, Inc., met its primary endpoint late last year. Pharmacokinetic, safety, and immunogenicity data for M923 compared with U.S.- and EU-sourced HUMIRA reference products will be presented.
Poster Presentation Details
Poster #FRI0182: A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (a Proposed Biosimilar to Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects
Presentation Date/Time: Friday, June 10, 2016; 11:45 a.m. local time
Presenter: Jan Hillson, MD; Vice President, Clinical Research, Momenta Pharmaceuticals
About M923, a proposed biosimilar of HUMIRA® (adalimumab)
M923 is developed in collaboration by Baxalta Incorporated, now part of Shire plc, and Momenta Pharmaceuticals. HUMIRA, the largest selling therapeutic on the market today, is a significant intervention for patients with autoimmune/inflammatory diseases. Adalimumab is used to treat many such conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
SOURCE: Momenta Pharmaceuticals
Post Views: 60
